View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 16, 2021

Oncology consultancy Physiomics signs new agreement with ValiRx

UK-based oncology consultancy company Physiomics has signed a new agreement with clinical stage drug development company ValiRx.

UK-based oncology consultancy company Physiomics has signed a new agreement with clinical stage drug development company ValiRx.

Physiomics noted that it supersedes the agreement that was signed between the companies in September 2011 to develop and accelerate the progress of ValiRx’s VAL201 anti-cancer compound.

As per the new agreement, ValiRx will benefit from Physiomics’ expertise in modelling the prostate cancer treatment effects.

It will also use Physiomics’ latest version of Virtual Tumour technology, which will be applied to get valuable information from the additional data generated by the VAL201 clinical trial.

ValiRx CEO Dr Suzy Dilly said: “Enhancing the scientific understanding of our results using cutting edge technology ensures we maximise the value of the data we have collected.

“This will help in the design and execution of future clinical trials and support discussions with potential new partners. We expect that outputs from the application of Physiomics’ technology will be incorporated into scientific publications presenting the results from the VAL201 clinical trial.”

Physiomics said it will also support ValiRx in modelling the VAL201 peptide use in endometriosis (VAL301) and Coronavirus (BC201).

So as to model the activity of a drug candidate, Physiomics ‘developed a quantitative systems pharmacology approach’ which uses clinical and pre-clinical data.

This data is used to explore the mechanism of action, impact of the disease as well as optimal dosing strategies.

Physiomics CEO Jim Millen said: “We are delighted to be working once again with ValiRx on a programme of work that replaces and extends that originally agreed in 2011.

“Since the time of the original agreement, Physiomics has gained significant additional experience in the modelling of prostate and other cancers and we will be aiming to generate new insights which can improve development outcomes.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena